ViroPharma added to Priority Stock List at Wells Fargo Wells Fargo believes that ViroPharma is meaningfully undervalued, as the company has strong fundamentals. The firm thinks that concerns over post-2015 Cinryze market share erosion are substantially overstated and it maintains an Outperform rating on the shares.
News For VPHM From The Last 14 Days
Check below for free stories on VPHM the last two weeks.
